PCE Home Study
Advances in the Management of Acute Myeloid Leukemia: Novel Therapies
Release Date: February 28, 2020
Expiration Date: February 27, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
The recent approval of several new agents and the ongoing development of additional novel therapies have ushered in a new age of treatment approaches for acute myeloid leukemia (AML). Because most newer drugs are targeted at specific genetic mutations, AML subsets, or patient populations, it has become critical to categorize AML in terms of cytogenetic and molecular profiles, in addition to clinical history, to facilitate therapeutic decision making. This activity focuses on ongoing advances in the treatment of AML, including appropriate use of novel therapies, management of therapy-related toxicities, and individualization of therapy.
Format
Interactive, audio-enhanced slide lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Describe diagnostic and prognostic steps and their roles in treatment selection for patients with AML
- Summarize the evidence supporting use of novel therapies for AML and the drug, patient, and disease characteristics that drive treatment choice
- Identify toxicities associated with novel AML therapies and strategies for managing them
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Chetasi Talati, MD
- Assistant Professor
- Department of Oncologic Sciences
- Assistant Member
- Malignant Hematology
- Moffitt Cancer Center
- University of South Florida
- Tampa, Florida
Corinne Williams, PA-C
- Physician Assistant
- Division of Hematology-Oncology
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Northwestern University Feinberg School of Medicine
- Chicago, Illinois
- Immediate Past President
- Association of Physician Assistants in Oncology
Details
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Stephanie Andrews, MS, ANP-BC, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 27, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Emilee Thomas, MMS, MPH, PA-C, Weill Cornell Medicine, New York, New York
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer, Inc; Bristol-Myers Squibb; Celgene Corporation; Eisai Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc, administered by Pharmacyclics, LLC; Taiho Oncology, Inc; and Sanofi Genzyme.
This activity is supported by an educational grant from Astellas.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Andrews: consultant: Amgen, AstraZeneca, Pfizer.
Dr Schwartzberg: consultant: Daiichi-Sankyo, OncoSec; speakers bureau: Genentech.
Dr Talati: advisory board: Daiichi-Sankyo, Pfizer; speakers bureau: Astellas Inc, Jazz Pharmaceuticals.
Ms Williams: consultant: AstraZeneca.
None of the members of the CE Alliance staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: February 28, 2020
Expiration date: February 27, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 96119OPCE-7G